Welcome!

News Feed Item

Infectious Diseases Point of Care Diagnostics - Products, Players and Outlook to 2017

NEW YORK, Feb. 25, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Infectious Diseases Point of Care Diagnostics - Products, Players and Outlook to 2017
http://www.reportlinker.com/p01105874/Infectious-Diseases-Point-of-Care-Diagnostics---Products-Players-and-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

With the variable impact of influenza testing and much product innovation, POC diagnostics for infectious diseases is a wide area of high-growth opportunities

The market for Point-of-Care (POC) diagnostic products used in infectious diseases is expected to exceed US$1.8 billion by 2017, with year-on-year double digit growth from 2013 onwards. But there is a twist...

One of the largest segments within POC infectious disease diagnostics is influenza testing (US$180 million in 2011) and the overall value of the sector is influenced by the demand for tests during the critical influenza season. For example, the market rose rapidly in 2009 as a result of increased demand brought about by the pandemic H1N1 virus, declined in 2010 when there was a weak influenza season and rose again in 2011 when rates of influenza were higher. The fragmented nature of the sector, along with variable factors such as the level of influenza testing, means any assessment of the market requires a detailed appreciation of the products and players driving growth.

Competitive landscape: plenty of room for expansion?
There are 80+ companies active in the POC infectious disease sector. Alere, with 2012 revenues of US$2.4 billion of which US$565 million were due to infectious disease tests, is clearly the market leader, providing tests across all major product sectors. Alere's success has been built, in part, due to an aggressive acquisition strategy. Could that route be taken by others?

Consolidation through mergers and acquisitions is likely to continue in the POC diagnostics market in the future, while some development-stage companies are likely to fail. In light of the current economic situation, there remain good opportunities for companies with cash or financing available to them to add to their POC operations, both through acquisitions and by licensing technologies from companies that cannot afford to commercialise them themselves.

Wide applications in different geographical settings
The market for POC infectious disease testing can be broadly divided into testing in the developed world, and testing in emerging and developing countries. In the developed world, POC testing is most frequently conducted in professional healthcare settings, where it facilitates faster diagnosis and treatment than lab-based testing. Demand in the developed world varies significantly, with the US a strong adopter of the technology and Japan also frequently using POC influenza testing products. However, testing in Europe continues to be conducted mainly in central labs and the POC market is underpenetrated, hence an area of good opportunity.

POC can also have a big impact in emerging markets. With access to central lab testing often being sparse or non-existent, particularly in remote areas, POC testing can determine diagnosis at the point of need and is playing a key role in reducing the prevalence of diseases such as HIV and Malaria.

Contents

EXECUTIVE SUMMARY 1

INTRODUCTION 2
The Role Of POC Testing in Infectious Disease Diagnostics and Surveillance 2
POC Infectious Disease Testing Products 3
Customers of POC Infectious Disease Tests 3
Regulatory and Reimbursement Environment 4
CLIA Waiver 4
CURRENT MARKET DYNAMICS 6
Fig 1: POC Diagnostics in Relation to the IVD Market, 2011 6
Fig 2: Percentage of POC Diagnostics Market by Product, 2011 7
Regional Perspective 7
Fig 3: Professional POC Diagnostics Market by Region, 2011 8
POC Infectious Disease Testing Market 8
Fig 4: POC Infectious Disease Testing Market, 2007-2011 (US$ million) 9
Fig:5: POC Infectious Disease Testing Market by Product Type, 2011 (%) 10
COMPETITIVE LANDSCAPE 11
Select POC Diagnostics Companies' Sales, 2007-2011 (US$ million) 11
POC Infectious Disease Competitors 11
Market Leaders for POC Infectious Disease Testing Products 12
Select Companies' Infectious Disease Testing Sales, 2008-2011 (US$ million) 12
Fig:6: POC Infectious Disease Testing Market Shares by Competitor, 2011 (%) 12
Merger and Acquisition Activity 12
Key POC Infectious Disease Testing Mergers and Acquisitions, 2008-2012 13
GROWTH DRIVERS, RESTRAINTS AND FUTURE OPPORTUNITIES 15
Clinical Utility and Accuracy 15
Expanded Access to Screening in the US 16
POC Diagnostics as a Disruptive Technology 16
Future Technology: Next-Generation POC Diagnostic Products 17
Detecting Hospital-Acquired Infections 17
Summary: Market Drivers, Restraints and Opportunities 18
MARKET OUTLOOK 19
Fig 7: POC Infectious Disease Testing Market, 2011-2017E (US$ million) 20
Fig 8: POC Infectious Disease Testing Market Growth Rates, 2008-2017E (US$ million) 20

PRODUCTS AND TECHNOLOGIES 21

POC RESPIRATORY DISEASE DIAGNOSTICS 21
POC Influenza Testing 21
Performance and Use of Rapid Influenza Tests in the US 21
CDC Recommendations 22
CDC: Influenza Prevalence and Test Accuracy 22
POC Influenza Testing Market 22
Future Prospects 23
CLIA-Waived Flu Detection Products 24
Alere's Influenza Tests 24
Alverix/Becton Dickinson's BD Veritor System 24
Quidel's Sofia Analyzer and Sofia Influenza A+B Fluorescent Immunoassays 25
Quidel's QuickVue Influenza Tests 25
SA Scientific's SAS FluAlert 25
Other POC Flu Detection Products 25
bioMérieux' bioNexia Influenza A+B Tests 26
IQuum's Liat Influenza A/B Assay and the Liat Analyzer 26
Jant Pharmacal's Accutest Flu Test 27
Medix Biochemica's Actim Influenza A&B 27
Meridian Bioscience's TRU FLU 27
Mizuho Medy's Quick Chaser Flu A,B 27
OraSure Technologies' OraSure QuickFlu Rapid Flu A+B Test 27
Princeton BioMeditech's BioSign Flu A+B 27
Response Biomedical's Influenza A+B Test 28
Sekisui Diagnostics' OSOM Influenza A & B Test 28
Products in Development 28
Alere's iNAT System 28
Chembio's DPP Influenza Tests 28
Cepheid's GeneXpert 29
Enigma Diagnostics 29
Enigma ML (Mini Laboratory) 30
Lucigen's Nucleic Acid-Based POC Test 31
Respiratory Syncytial Virus Testing 31
Alverix/BD's BD Veritor System 32
Quidel's Sofia RSV Fluorescent Immunoassay 32
Quidel's QuickVue RSV 10 33
Response Biomedical's RSV Test 33
BioFire Diagnostics' FilmArray System 33
FilmArray Respiratory Panel 34
Other Respiratory Tests 34
Ani Biotech's Biocard Chlamydia Pneumoniae IgM Test 34
GenBio's ImmunoFLOW Mycoplasma IgM Test 34
Trinity Biotech's Uni-Gold Tests 35
OTHER PRIMARY CARE POC TESTS 36
Group A Streptococcus Tests 36
Currently Available POC Tests 36
Quidel's Sofia Strep A Fluorescent Immunoassay 37
H pylori Tests 37
Currently Available H pylori Tests 38
Exalenz Bioscience's BreathID System 38
Otsuka America Pharmaceutical's BreathTek UBT 39
Mononucleosis Tests 39
Currently Available POC Tests 39
Rotavirus and Adenoviral Enteritis Tests 40
Ani Biotech's Biocard Tests 40
Meridian Bioscience ImmunoCard STAT! Rotavirus 40
Nicox/Rapid Pathogen Screening's AdenoPlus 40
Orion Diagnostica's Diarlex, Rotalex and Adenolex Tests 40
Other Products 41
Ani Biotech's Biocard Candida and Trichomonas Tests 41
Gryphus Diagnostics' BVBLUE 41
Medix Biochemica's Actim Noro 41
POC HIV TESTING 42
Fig 9: HIV Prevalence, 2001-2011 (millions) 42
Fig 10: HIV Prevalence by Region, 2011 43
Fig 11: Number of New HIV Infections, 2001-2011 (million) 43
Fig 12: New HIV Infections by Region, 2011 44
Efforts to Combat HIV 44
Screening in the US 44
The Role of POC Testing 45
Market Dynamics 46
Fig:13: Global POC HIV Testing Market Shares by Company, 2011 47
Fig:14: US POC HIV Testing Market Shares by Company, 2011 47
Rapid HIV Tests 48
Currently Available POC Tests 48
CLIA-Waived Tests 49
bioLytical Laboratories' INSTI Rapid HIV-1 Antibody Test 49
Chembio Diagnostics' Lateral Flow HIV Tests 49
Fig 15: Chembio: HIV Lateral Flow Test Sales, 2008-2011 (US$ thousands) 50
OraSure Technologies' OraQuick Rapid Test Platform 50
OraSure's POC HIV Testing Sales, 2010-2011 (US$ thousands) 50
Fig 16: OraSure's OraQuick HIV Revenue by Region, 2011 51
Trinity Biotech's POC HIV Tests 51
Non-CLIA-Waived Tests 52
Alere's SD, Determine and Clearview HIV Tests 52
bioMérieux's VIKIA HIV 1/2 HIV Test 52
Bio-Rad's Multispot HIV-1/HIV-2 Rapid Test 52
Calypte Biomedical's Aware HIV-1/2 Tests 52
Fig 17: Calypte Biomedical: Aware Rapid HIV Test Sales, 2009-2011 (US$ thousands) 53
Chembio's Dual Path Platform Technology Products 53
FirstVue HIV Tests 54
Hema Diagnostic Systems 55
IND Diagnostic's One-Step Anti-HIV (1+2) Tests 55
Lab21's Biotec Tests 55
MedMira's Reveal HIV Tests 55
Savyon Diagnostics' HIVSav 1/2/0 Rapid SeroTest 56
Unimed's FirstSign HIV Duo 57
Products in Development 57
Alere's NAT Analyzer 57
Calypte Biomedical's Aware II (The Ani Platform) 57
Cepheid's GeneXpert System and Xpert HIV Viral Load Test 57
Chembio's SURE CHECK HIV OTC 58
IQuum's Liat System 58
MedMira's Dual HIV Test 58
POC CD4 Testing 59
Alere's Pima Point-of-Care CD4 Analyser 59
In Development - Daktari Diagnostics' Daktari CD4 59
POC HEPATITIS TESTS 61
Hepatitis B 61
Hepatitis C 61
HCV Screening in the US 62
POC HCV Testing 63
POC and Rapid HCV Tests: Sensitivity & Specificity 63
Available POC Tests 64
Key Rapid Tests 65
Alfa Scientific Designs' Instant-View Tests 65
bioMérieux's VIKIA HBs Ag Test 65
FirstVue's Hepatitis Rapid Test Kits 66
OraSure Technologies' OraQuick HCV Rapid Antibody Test 66
OraSure's POC HCV Testing Sales, 2010-2011 (US$ thousands) 66
Fig 18: OraQuick HCV Revenue by Region, 2011 67
Runbio Biotech's One Step Tests 67
In Development 67
bioLytical Laboratories' INSTI Test 67
Chembio Diagnostics' DPP HCV Test 68
MedMira's Rapid Tests 68
COMBINATION POC TESTS 70
TB and HIV 70
MedMira's Multiplo Rapid Tests 70
Multiplo HIV/HCV 70
Multiplo HBV/HIV/HCV 71
Multiplo TP/HIV 71
Products in Development 71
Chembio Diagnostics' DPP Syphilis/HIV Combination Test 71
MedMira's Development Products 71
POC TUBERCULOSIS TESTING 72
Multidrug-Resistant TB 72
TB and HIV 73
POC TB Testing 73
Cepheid's Xpert MTB/RIF 74
Concessionary Pricing 75
Alere's Determine TB LAM Ag Test 75
Products In Development 76
Alere/TwistDx's Recombinase Polymerase Amplification Technology 76
Applied Nanodetectors and the London School of Hygiene & Tropical Medicine 76
Chembio's DPP Tuberculosis Test 76
Enigma Diagnostics' Enigma ML (Mini Laboratory) 77
POC SEXUALLY-TRANSMITTED INFECTION TESTING 78
STI Testing and the Role of POC Diagnostics 78
POC STI Diagnostic Products 79
Currently Available POC Tests 79
Ani Biotech's Biocard Candida and Trichomonas Tests 80
Focus Diagnostics' HerpeSelect Express HSV-2 80
Gryphus Diagnostics' BVBLUE 80
Hema Diagnostic Systems' Rapid 1-2-3 Hema Syphilis 80
MedMira's Reveal TP Rapid Syphilis Test 80
Quidel's QuickView Chlamydia Test 80
RunBio Biotech's Tests 81
Savyon Diagnostics' SavvyCheck 81
Sekisui Diagnostics' OSOM Tests 81
Trinity Biotech's Uni-Gold HSV-2 Rapid Test 81
Products In Development 81
Atlas Genetics' POC System 81
bioLytical Laboratories' INSTI Test 82
Chembio's DPP Syphilis Tests 82
GenBio's ImmunoFLOW Herpes Simplex Virus Test 83
Randox Laboratories' Lab-on-a-Chip 83
POC TROPICAL DISEASE TESTS 85
Common Tropical Diseases 85
Malaria 85
Dengue Fever 85
Leptospirosis 86
Visceral Leishmaniasis 86
Typhoid 86
POC Testing 87
Currently Available POC Tests 88
Alere's Standard Diagnostics Tests 88
SD BIOLINE HAT 88
Hema Diagnostic Systems' Malaria and Typhoid Tests 89
Lab21's Tropical Disease Tests 89
Quest Diagnostics' Focus Dengue Rapid Tests 89
Products in Development 90
Chembio's DPP Leptospirosis 90
Chembio's DPP Visceral Leishmaniasis 90
EMERGING TECHNOLOGIES 91
POC Hospital-Acquired Infection Testing 91
Available Products and Developments 93
New-Generation POC Diagnostic Platform Technologies 93
Alere's POC Molecular Diagnostics Technologies 93
Ionian Technologies' Nicking Enzyme Amplification Reaction Technology 94
TwistDx' Recombinase Polymerase Amplification Technology 94
Atlas Genetics' POC System 94
Atonomics' Atolyzer 95
Bio-AMD's MPR and DSR 96
BioFire Diagnostics' FilmArray System 97
FilmArray Blood Culture ID Panel 97
FilmArray GI Panel 97
Biosensia's RapiPlex 98
Cepheid's GeneXpert 98
pes diagnosesysteme' respons IQ 99
Enigma Diagnostics' Products 100
Enigma ML (Mini Laboratory) 100
ResonSense Technology 101
Fiomi Diagnostics (Trinity Biotech) Forecast Technology 102
Immunexpress' SeptiCyte Technology 102
IQuum's Liat System 103
Liat Assays 104
Lucigen's Nucleic Acid-Based POC Tests 104
MycroLab 105
OPKO Health's OPKO Diagnostics Platform 106
Philips' Minicare 106
Radisens Diagnostics' POC Platform 107
Randox Laboratories' Lab-on-a-Chip 107
ReLIA Diagnostic Systems' ReLIA System 108
Rheonix' EncompassMDx Platform 108
T2 Biosystems' T2Dx System 108
Infectious Diseases 109
Tyrian Diagnostics' DiagnostIQ 110

POC MANUFACTURERS 111

POC COMPANY DIRECTORY 111

SELECTED COMPANY PROFILES 115

Alere 115
Recent Key Events 116
POC Infectious Disease Tests 116
New Products 116
Standard Diagnostics' Tests 117
Research and Development 118
Infectious Diease Mergers & Acquisitions 118
Ionian Technologies 118
TwistDx 118
Standard Diagnostics 119
Mologic, Jinsung Meditech, Biolinker and Long Chain International Corp 119
ACON Laboratories' Rapid Diagnostics Assets 119
Matria Healthcare 119
BBI Holdings 119
Other Acquisitions 120
Contracts and Alliances 120
OraSure Technologies 120
Chembio 120
Trinity Biotech 121
Financial Performance 121
Alere - Operating Results, 2007-2011 (US$ million) 121
Fig 19: Percentage of Alere's Revenue by Segment, 2011 122
Fig 20: Percentage of Alere's Revenue by Region, 2011 122
Alere Professional Diagnostics: Operating Results, 2007-2011 (US$ million) 122
Alere Professional Diagnostics: Net Sales & Services Revenue, 2007-2011 (US$ million) 123
Fig 21: Alere Professional Diagnostics: Net Sales & Services Revenue by Product, 2011 123
Latest Results 123
Calypte Biomedical 124
Aware Rapid Test Product Line 124
Aware HIV-1/2 OMT (Oral fluid) 125
Aware HIV-1/2 Oral OTC 125
Products in Development - Aware II (The Ani Platform) 125
Current Alliances 125
Manufacturing Contracts 126
Financial Performance 126
Calypte Biomedical: Operating Results, 2007-2011 (US$ thousands) 126
Calypte Biomedical: Revenue by Product Line, 2009-2011 (US$ thousands) 127
Fig 22: Calypte Biomedical: Percentage of Revenue by Product Line, 2011 127
Latest Results 127
Chembio Diagnostics 128
Recent Key Events 129
Lateral Flow Rapid HIV Tests 129
Dual Path Platform Technology Products 130
DPP HIV 1/2 Assay 130
DPP HIV 1/2 Confirmatory Test 130
Other Tests 131
Research and Development 131
SURE CHECK HIV OTC 131
DPP Technology Products in Development 131
Current Alliances and Contracts 133
Battelle Memorial Institute 133
Oswaldo Cruz Foundation of Brazil 133
National Institutes of Health 134
Alere 134
Infectious Disease Research Institute 134
Bio-Rad Laboratories 134
Financial Performance 135
Chembio - Operating Results, 2007-2011 (US$ thousands) 135
Chembio - Revenue by Type, 2008-2011 (US$ thousand) 136
Chembio - Product Sales by Region, 2010-2011 (US$ thousand) 136
Fig 23: Percentage of Chembio's Revenue by Type, 2011 136
Fig 24: Percentage of Chembio's Product Sales by Region, 2011 137
Latest Results 137
MedMira 138
Recent Key Events 139
Rapid Tests 139
Multiplo HIV/HCV 139
Multiplo HBV/HIV/HCV 140
Multiplo TP/HIV 140
Reveal HIV Tests 140
Reveal TP Rapid Syphilis Test 141
Reveal/MedMira hp Test H pylori Test 141
R&D Activities 141
Dual HIV Test 142
Current Alliances 142
United States Army 142
Advance Aid 143
Triplex International Biosciences 143
VWR International 143
Vitest 143
Financial Performance 143
MedMira - Operating Results, 2008-2012 (C$ thousands) 144
MedMira - Revenue by Region, 2007-2012 (C$ thousands) 144
Fig 25: MedMira - Revenue by Region, 2012 145
Latest Results 145
Meridian Bioscience 146
TRU FLU and TRU RSV 146
ImmunoCard STAT! HpSA H pylori Test 146
ImmunoCard STAT! Rotavirus 146
ImmunoCard STAT! Strep A 146
ImmunoCard STAT! MONO 146
ImmunoCard STAT! hCG Combo Test 147
Financial Performance 147
Meridian Bioscience - Operating Results, 2008-2012 (US$ million) 147
Meridian Bioscience - Third-Party Sales by Segment, 2008-2012 (US$ million) 147
Meridian Bioscience - Operating Income by Segment, 2008-2012 (US$ million) 147
Fig 26: Meridian Bioscience - Revenue by Segment, 2012 148
Meridian Bioscience - European Diagnostics Sales by Country, 2006-2011 (US$ million) 148
Outlook 148
OraSure Technologies 149
Recent Key Events 149
OraQuick Rapid Test Platform 149
OraSure's OraQuick ADVANCE HIV Test 149
OraSure's OraQuick In-Home HIV Test 150
OraQuick HCV Rapid Antibody Test 150
OraSure QuickFlu Rapid Flu A+B Test 150
Products in Development 150
Current Alliances and Licensing Agreements 150
Princeton BioMeditech 150
Alere 151
Merck 151
Ortho-Clinical Diagnostics 151
Financial Performance 151
OraSure - Operating Results, 2007-2011 (US$ million) 152
Fig 27: OraSure - Revenue by Business Area, 2011 152
OraSure Infectious Disease Testing Sales, 2010-2011 (US$ thousands) 153
Fig 28: OraQuick HIV Revenue by Region, 2011 153
Fig 29: OraQuick HCV Revenue by Region, 2011 153
Latest Results and Outlook 154
Quest Diagnostics 155
Focus Diagnostics' POC Products 155
HerpeSelect Express HSV-2 155
Focus Dengue Rapid Tests 156
Financial Performance 156
Quest Diagnostics - Operating Results, 2007-2011 (US$ million) 157
Quest Diagnostics - Sales and Earnings by Category, 2007-2011 (US$ million) 157
Fig 30: Quest Diagnostics - Revenue by Division, 2011 157
Latest Results and Outlook 157
Quidel 159
Recent Key Events 159
Sofia Analyzer and the Sofia Influenza A+B Fluorescent Immunoassay 159
QuickVue Rapid Tests 160
QuickVue Influenza Tests 160
QuickVue Group A Strep Tests 160
QuickVue RSV Tests 160
QuickVue+ Infectious Mononucleosis 161
QuickVue H Pylori gII Test 161
Financial Performance 161
Quidel - Operating Results, 2007-2011 (US$ million) 161
Quidel - Revenue by Product Type, 2008-2011 (US$ million) 162
Fig 31: Quidel - Revenue by Product Type, 2011 162
Fig 32: Quidel - Infectious Disease Revenue, 2005-2011 (US$ million) 162
Quidel - Revenue by Region, 2005-2011 (US$ million) 163
Fig 33: Quidel - Revenue by Region, 2011 163
Latest Results and Outlook 163
Sekisui Diagnostics 164
Point of Care Tests 164
OSOM RSV/Adenovirus Rapid Test 164
OSOM Influenza A & B Test 164
OSOM H pylori 164
OSOM Ultra Strep A 164
OSOM Strep A 165
OSOM Mono 165
OSOM Trichomonas Rapid Test 165
OSOM BVBLUE Test 165
OSOM C difficile Toxin A/B Test 165
Thermo Fisher Scientific 166
Sure-Vue Tests 166
Remel's Xpect Tests 167
Trinity Biotech 168
POC HIV Tests 168
Uni-Gold Recombigen HIV 168
Other POC Tests 169
Uni-Gold Giardia Test 169
Uni-Gold HSV-2 Rapid 169
Uni-Gold Legionella Urinary Antigen PLUS 169
Fiomi Diagnostics 169
Alere Licence 170
Financial Performance 170
Trinity Biotech Operating Results, 2007-2011 (US$ million) 170
Trinity Biotech - Sales by Product Line, 2006-2011 (US$ million) 171
Fig 34: Trinity Biotech - Sales by Product Type, 2011 171
Latest Results and Outlook 171

APPENDICES 172

APPENDIX 1 - LIST OF ABBREVIATIONS 172
APPENDIX 2 - REPORT METHODOLOGY 173


To order this report:
In_Vitro_Diagnostic Industry:
Infectious Diseases Point of Care Diagnostics - Products, Players and Outlook to 2017

 

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The paradigm has shifted. A Gartner survey shows that 43% of organizations are using or plan to implement the Internet of Things in 2016. However, not just a handful of companies are still using the old-style ad-hoc trial-and-error ways, unaware of the critical barriers, paint points, traps, and hidden roadblocks. How can you become a winner? In his session at @ThingsExpo, Tony Shan will present a methodical approach to guide the holistic adoption and enablement of IoT implementations. This ov...
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, will explain how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.
In his session at 18th Cloud Expo, Sagi Brody, Chief Technology Officer at Webair Internet Development Inc., will focus on real world deployments of DDoS mitigation strategies in every layer of the network. He will give an overview of methods to prevent these attacks and best practices on how to provide protection in complex cloud platforms. He will also outline what we have found in our experience managing and running thousands of Linux and Unix managed service platforms and what specifically c...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists will dis...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
SYS-CON Events announced today that Stratoscale, the software company developing the next generation data center operating system, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Stratoscale is revolutionizing the data center with a zero-to-cloud-in-minutes solution. With Stratoscale’s hardware-agnostic, Software Defined Data Center (SDDC) solution to store everything, run anything and scale everywhere...
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...
Angular 2 is a complete re-write of the popular framework AngularJS. Programming in Angular 2 is greatly simplified – now it's a component-based well-performing framework. This immersive one-day workshop at 18th Cloud Expo, led by Yakov Fain, a Java Champion and a co-founder of the IT consultancy Farata Systems and the product company SuranceBay, will provide you with everything you wanted to know about Angular 2.
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
You deployed your app with the Bluemix PaaS and it's gaining some serious traction, so it's time to make some tweaks. Did you design your application in a way that it can scale in the cloud? Were you even thinking about the cloud when you built the app? If not, chances are your app is going to break. Check out this webcast to learn various techniques for designing applications that will scale successfully in Bluemix, for the confidence you need to take your apps to the next level and beyond.
Unless you don’t use the internet, don’t live in California, or haven’t been paying attention to the recent news… you should be aware that self-driving cars are on their way to becoming a reality. I have seen them – they are real. If you believe in the future reality of self-driving cars, then continue reading on. If you don’t believe in the future possibilities, then I am not sure what to do to convince you other than discuss the very real changes that will roll out with the consumer producti...
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, will discuss how leveraging the Industrial Interne...